X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA WOCKHARDT LTD. SHASUN PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 123.9 -15.2 - View Chart
P/BV x 8.5 2.5 341.7% View Chart
Dividend Yield % 0.2 1.3 17.7%  

Financials

 SHASUN PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
WOCKHARDT LTD.
Mar-17
SHASUN PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs941,129 8.3%   
Low Rs46627 7.3%   
Sales per share (Unadj.) Rs214.2363.1 59.0%  
Earnings per share (Unadj.) Rs5.3-20.4 -26.1%  
Cash flow per share (Unadj.) Rs15.8-7.0 -226.8%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %1.41.1 125.6%  
Book value per share (Unadj.) Rs53.3301.8 17.7%  
Shares outstanding (eoy) m56.62110.55 51.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.32.4 13.5%   
Avg P/E ratio x13.1-42.9 -30.5%  
P/CF ratio (eoy) x4.4-125.9 -3.5%  
Price / Book Value ratio x1.32.9 45.0%  
Dividend payout %18.7-48.9 -38.3%   
Avg Mkt Cap Rs m3,95897,063 4.1%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1649,665 22.4%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m12,12740,146 30.2%  
Other income Rs m2291,143 20.1%   
Total revenues Rs m12,35641,289 29.9%   
Gross profit Rs m1,009128 788.3%  
Depreciation Rs m5941,489 39.9%   
Interest Rs m4152,253 18.4%   
Profit before tax Rs m230-2,472 -9.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73-211 34.4%   
Profit after tax Rs m302-2,260 -13.4%  
Gross profit margin %8.30.3 2,609.7%  
Effective tax rate %-31.78.5 -370.7%   
Net profit margin %2.5-5.6 -44.2%  
BALANCE SHEET DATA
Current assets Rs m6,88446,160 14.9%   
Current liabilities Rs m8,45619,258 43.9%   
Net working cap to sales %-13.067.0 -19.3%  
Current ratio x0.82.4 34.0%  
Inventory Days Days62101 61.2%  
Debtors Days Days10894 114.4%  
Net fixed assets Rs m4,97040,165 12.4%   
Share capital Rs m113553 20.5%   
"Free" reserves Rs m2,87532,814 8.8%   
Net worth Rs m3,02033,367 9.1%   
Long term debt Rs m1,81731,903 5.7%   
Total assets Rs m13,34789,687 14.9%  
Interest coverage x1.6-0.1 -1,599.3%   
Debt to equity ratio x0.61.0 62.9%  
Sales to assets ratio x0.90.4 203.0%   
Return on assets %5.40 -62,590.3%  
Return on equity %10.0-6.8 -147.7%  
Return on capital %13.3-0.3 -3,974.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,8439,121 64.1%   
Fx outflow Rs m2,1732,133 101.9%   
Net fx Rs m3,6696,988 52.5%   
CASH FLOW
From Operations Rs m398-2,695 -14.8%  
From Investments Rs m-1,635-6,863 23.8%  
From Financial Activity Rs m1,30912,545 10.4%  
Net Cashflow Rs m713,010 2.4%  

Share Holding

Indian Promoters % 39.2 74.5 52.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 2.3 156.5%  
FIIs % 17.6 7.7 228.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 39.6 15.4 257.1%  
Shareholders   20,750 67,757 30.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS